NYU Langone Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).
NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.
NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,164 total, page 11 of 24
Evaluation of Patient Education Simulations to Promote Health and Wellness
NCT04352179
Radiographic and Clinical Comparison of Post-reduction Splinting Constructs in the Treatment of Acute Displaced Distal Radius Fractures
NCT03570905
Evaluating the Impact of a Supportive Care Program
NCT04971278
Impact of Prisma on Donor Site Pain
NCT04050124
Fenfluramine in CDKL5 Deficiency Disorder (CDD)
NCT03861871
Trial of Community Health Worker-led Decision Coaching
NCT03726320
Teachers Thriving Together
NCT03980834
Brain Plasticity Underlying Acquisition of New Organizational Skills in Children
NCT04108273
Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty
NCT04075526
Cannabidiol as a Treatment for AUD Comorbid With PTSD
NCT03248167
Nivolumab Combined With BMS-986253 in HCC Patients
NCT04050462
Effects of Cannabidiol in Alcohol Use Disorder
NCT03252756
Safety and Feasibility of a Novel In--Bed Resistance Training Device in Elderly Inpatients
NCT04026802
Anti-stigma Intervention for Chinese American Older Adults
NCT03820297
Patient Satisfaction With Virtual Postoperative Visit
NCT04108442
Implementing a Digital Child Mental Health Screening, Literacy, and Management Tool in Faith-Based Settings
NCT03651050
Effects of a Three-Month Low Calorie Diet Weight Loss Intervention on Knee Replacement Outcomes
NCT04015011
Expanding PrEP By Embedding Unannounced SNAPS Navigators in High STI Testing Clinical Sites
NCT04207151
Neuropsychological Consultation as Part of Pediatric Diabetes Care: Does it Improve Glycemic Control and Family Functioning?
NCT03653013
Parent Understanding of Discharge Instructions
NCT04063241
Hippocampal Memory Circuits in Delusions
NCT03822910
Diabetes Management Intervention For South Asians
NCT03333044
Primary Palliative Care for Emergency Medicine (PRIM-ER)
NCT03424109
Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department
NCT04281030
XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept
NCT03604159
Polyp Measurement Device
NCT03856255
High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
NCT03945591
Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)
NCT04009083
High Level Mobility Training in Ambulatory Patients With Acquired Non-progressive Central Neurological Injury
NCT04063228
Heartmath Migraine Study
NCT04077658
NIDEK Gonioscope GS-1 for Glaucoma
NCT03715231
Efficacy and Mechanisms of Energy Medicine to Decrease Chronic Knee Pain in Outpatient Settings
NCT03637595
Rheumatoid Arthritis Memory B Cells and Abatacept
NCT03652961
Pilot Usability and Feasibility Testing on Kinect-Enhanced Training System for Lymphatic Exercises
NCT03999177
Colchicine for the Treatment of Osteoarthritis of the Knee
NCT03913442
Pilot Study of New Computer-based Neuropsychological Tool: Visual Tests, Touch Responses
NCT03502603
ED-Home Pilot Study
NCT03864341
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
NCT03718143
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
NCT03742986
Neural Mechanisms of Cost and Benefit Integration During Decision-Making, Aim 2: Acute & Lifetime Stress
NCT04060966
PhosphoRus, Proton Imaging and Amyloid BuRdEn (PREPARE) ON AMYLOID BURDEN AND COGNITION
NCT03999879
P20 Extending Sleep to Reverse Metabolic Syndrome
NCT03596983
A Study of the Effects of Lavender Aromatherapy on Preoperative Anxiety in Breast Surgery Patients
NCT03445130
tDCS for the Management of Multiple Sclerosis Related Fatigue
NCT03838770
Accuracy of Non-invasive Non-oscillometric Blood Pressure Wristband
NCT03629535
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
NCT03837353
Diabetes Prevention for Black Men
NCT03708380
Cannabidiol for ASD Open Trial
NCT03900923
CLEAR SYNERGY Neutrophil Substudy
NCT03874338
Application of Cervical Elastography in Obstetrics
NCT03902587
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 99 |
| Phase 2 | 132 |
| Phase 3 | 28 |
| Phase 4 | 95 |
Therapeutic Areas
What is open in the NYU Langone Health pipeline
197 recruiting of 1,164 indexed (17% open); 741 completed (64%).
Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NYU Langone Health: open-pipeline peers nationwide
Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,164 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
- University of Utah · 17% recruiting · 818 trials
Related
What to do with this NYU Langone Health page
1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.
- 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.